基本信息
views: 6
Career Trajectory
Bio
Pro's research focus on clinical trials for the application of targeted therapeutic agents is helping to improve outcomes for patients with aggressive lymphoma subtypes. Her work has led to FDA approval of several novel agents, including pralatrexate, romidepsin, and brentuximab vedotin.
Pro's research focus on clinical trials for the application of targeted therapeutic agents is helping to improve outcomes for patients with aggressive lymphoma subtypes. Her work has led to FDA approval of several novel agents, including pralatrexate, romidepsin, and brentuximab vedotin.
Pro's research focus on clinical trials for the application of targeted therapeutic agents is helping to improve outcomes for patients with aggressive lymphoma subtypes. Her work has led to FDA approval of several novel agents, including pralatrexate, romidepsin, and brentuximab vedotin.
Research Interests
Papers共 354 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
BLOOD ADVANCESno. 7 (2024): 1612-1620
LEUKEMIA & LYMPHOMAno. 6 (2024): 1-10
Neha Mehta–Shah,Eric Jacobsen, Pier Luigi Zinzani,Jasmine Zain,Monica Mead,Carla Casulo,Giuseppe Gritti,Lauren Pinter‐Brown,Koji Izutsu, Sheila Waters,Jonathan E. Brammer,Barbara Pro,
HemaSphereno. S3 (2023): e3891642-e3891642
Hematological Oncologyno. S2 (2023): 833-834
BLOODno. 17 (2023): 1426-1437
Cited0Views0Bibtex
0
0
Nicholas Kendsersky,Rebecca Masel,Amman Bhasin,Tingting Zhan,Carol Gung,Mercy George,Frederick Michael Fellin,Allison Zibelli, Avnish Bhatia, Rajan Singla,Michael Ramirez,Andrew E. Chapman,
Blood Advancesno. 12 (2023): 2670-2676
Hematological oncology (2023)
Hematological Oncologyno. S2 (2023): 499-500
Load More
Author Statistics
#Papers: 350
#Citation: 12897
H-Index: 51
G-Index: 107
Sociability: 7
Diversity: 2
Activity: 49
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn